The agency first approved Avycaz in 2015 to treat adults with intra-abdominal infections in combination with metronidazole. In 2016, the FDA OK’d the antibiotic to treat complicated urinary tract infections and kidney infections.
Clinicians may now use Avycaz to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, both caused by drug-resistant bacteria.
More articles on supply chain:
10 most-read supply chain stories in January
FDA approves record number of personalized medicines in 2017: 4 things to know
FDA approves treatment for C. diff-associated diarrhea: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.